NCT03823378

A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With an Active Drug Given Alone or in Combination With an Active Drug.

Brief summary

This is a long-term extension (LTE) study to assess the safety, tolerability and efficacy of an active drug and an active drug in Rheumatoid Arthritis (RA) participants who have completed M16-063

Interventional study

Status:
Terminated
Conditions:
Rheumatoid Arthritis (RA)
Enrollment:
97 patients
Phase:
  • 1
  • 2
  • 3
  • 4
Protocol ID:
M16-763
Allocation:
Randomized
Intervention model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Purpose:
Treatment

Would you like to know more about this trial?

Yes, please contact me

Eligibility criteria

Participant attributes:
Male and Female

Age:

18 Years and older.

Inclusion Criteria: - Participant has completed Study M16-063 - Participant has not developed any laboratory or clinical discontinuation criteria as defined in the Study M16-063 protocol - Participant is willing and/or able to comply with procedures required in the current study protocol Exclusion Criteria: - Participant is currently enrolled or planning to enroll in another interventional clinical study while participating in this study (except the preceding study M16-063) - Participant requires vaccination with any live vaccine during study participation, including at least 30 days after the last dose of study drug

All the cities where the clinical studies are located